NASDAQ:ASRT

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Nexus, Complaint, Acquisition, Prospectus, Register, Spectrum, Dada, Marketing, FDA, News, Food, Sale, CMI, Form, Adjustment, Risk, Learning, IPO, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, EPS, P.C, Audit

For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

Key Points: 
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS
    Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Cummins class action go to: https://bespc.com/cases/CMI

ASRT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Assertio Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, February 26, 2024
Court, Person, Spectrum, Sale, Complaint, Risk

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ASRT .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ASRT .
  • The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ASRT 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Assertio Holdings (ASRT) Investors with Substantial Losses to Contact Firm Before Mar. 5th Deadline in Securities Fraud Class Action

Retrieved on: 
Sunday, February 25, 2024
SAN, Person, Spectrum, FDA, Suppository, News, Sale, Risk, Hagens Berman, ASRT, EPS, Pressure, Cryptocurrency

SAN FRANCISCO, Feb. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Assertio Holdings, Inc. (NASDAQ: ASRT) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Assertio Holdings, Inc. (NASDAQ: ASRT) investors who suffered substantial losses to submit your losses now .
  • Assertio Holdings, Inc. (ASRT) Securities Fraud Class Action:
    On Jan. 4, 2024, securities analyst Sidoti & Company lowered its price target of Assertio Holdings (ASRT) shares by 25% and also significantly cut its 2024 and 2025 revenue estimates.
  • First, on Jan. 5, ASRT shares nose-dived after the Company announced that CEO Dan Peisert was stepping down.
  • Notably, Assertio characterized Peisert’s separation from the company as an “involuntary termination.”
    Second, immediately following Peisert’s termination, ASRT investors filed a securities fraud class action suit alleging Assertio securities were artificially inflated for the period of Mar.

ASRT CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Sunday, February 25, 2024
Acquisition, Court, Person, FDA, News, Fraud, CFTC, District court, Adjustment, Lead, Q3, Suppository, Medicare, IRS, LLP, EPS, COPY

The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Assertio’ s materially misleading statements and omissions to the public, Assertio’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Assertio investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Assertio, Shapiro v. Assertio Holdings, Inc., et al., Case No.

ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Acquisition, Court, Spectrum, FDA, News, Food, Advertising, Sale, Learning, Adjustment, Risk, Woman, Suppository, Spectrum Pharmaceuticals, LLP, EPS, Cryptocurrency

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) and reminds investors of the March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the "Spectrum Acquisition").
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Assertio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

ASRT 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Assertio Holdings (ASRT) Investors with Substantial Losses to Contact Firm Before Mar. 5th Deadline in Securities Fraud Class Action

Retrieved on: 
Thursday, February 22, 2024
SAN, Person, Spectrum, FDA, Suppository, News, Sale, Risk, Hagens Berman, ASRT, EPS, Pressure, Cryptocurrency

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Assertio Holdings, Inc. (NASDAQ: ASRT) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Assertio Holdings, Inc. (NASDAQ: ASRT) investors who suffered substantial losses to submit your losses now .
  • Assertio Holdings, Inc. (ASRT) Securities Fraud Class Action:
    On Jan. 4, 2024, securities analyst Sidoti & Company lowered its price target of Assertio Holdings (ASRT) shares by 25% and also significantly cut its 2024 and 2025 revenue estimates.
  • First, on Jan. 5, ASRT shares nose-dived after the Company announced that CEO Dan Peisert was stepping down.
  • Notably, Assertio characterized Peisert’s separation from the company as an “involuntary termination.”
    Second, immediately following Peisert’s termination, ASRT investors filed a securities fraud class action suit alleging Assertio securities were artificially inflated for the period of Mar.

DEADLINE ALERT for MSS, ASRT, DADA, BNTX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, February 22, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Suite, The Company, BioNTech, Spectrum, Class, Investment, Marketing, Telephone, Sale, Risk, COVID-19, EB-5, Law, Supermarket

BENSALEM, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

ASRT Lead Plaintiff Deadline Approaching: Assertio Holdings, Inc. Shareholders Should Contact Robbins LLP for Information About the Class Action Against ASRT

Retrieved on: 
Thursday, February 22, 2024
Acquisition, Person, Spectrum, FDA, News, Sale, Risk, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Integration, Patient, LLP, ASRT

Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.

Key Points: 
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Assertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ASRT

Retrieved on: 
Thursday, February 22, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT

NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Assertio Holdings investors who were adversely affected by alleged securities fraud between March 29, 2023 and November 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against VNET, Assertio, Cummins, and Brooge and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 22, 2024
Complaint, Acquisition, Spectrum, FDA, News, Food, BIA, Sale, Fraud, CMI, Adjustment, Risk, Cayman, Suppository, Rheumatoid arthritis, Executive, Spectrum Pharmaceuticals, Patient, ASRT, Security (finance), Facility, EPS, Defendant, Learning, P.C

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the Company’s share price fell $0.20, or 3.2% on February 13, 2023, on unusually heavy trading volume.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Brooge class action go to: https://bespc.com/cases/BROG